Moreover, treatment of MLL-rearranged AML with the LSD1 inhibitor GSK-LSD1 caused global gains in chromatin accessibility, with a strong enrichment of PU.1 and C/EBPα at these open sites. The gene discussed is KMT2A; the disease is acute myeloid leukemia.